| Stereochemistry | ACHIRAL |
| Molecular Formula | C7H8N6 |
| Molecular Weight | 176.1786 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C1CC2=C(C1)C(=NN2)C3=NN=NN3
InChI
InChIKey=LTQYSJKGRPGMPO-UHFFFAOYSA-N
InChI=1S/C7H8N6/c1-2-4-5(3-1)8-9-6(4)7-10-12-13-11-7/h1-3H2,(H,8,9)(H,10,11,12,13)
Originator
Approval Year
Cmax
AUC
T1/2
Sourcing
PubMed
Patents
Sample Use Guides
In a phase II study MK-0354 was administred daily at dose 2.5g for 4 weeks.
Route of Administration:
Oral
Equilibrium binding of [3H]nicotinic acid was done with membranes (30 μg/assay) from CHO-K1 cells, transfected with GPR109a, and test compound diluted in assay buffer (20 mM HEPES, pH 7.4, 1 mM MgCl2, and 0.01% CHAPS) in a total volume of 200 uL. After 4 h at room temperature, reactions were filtered through Packard Unifilter GF/C plates using a Packard Harvester and washed eight times with 200 μl of ice-cold binding buffer. Nonspecific binding was determined in the presence of 250 μM unlabeled nicotinic acid. Competitive binding assays were performed in the presence of 50 nM [3H]nicotinic acid.
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
